References
1. Rubnitz JE. Current Management of Childhood Acute Myeloid Leukemia.
Paediatr Drugs 2017:19(1):1-10.
2. Bolouri H, Farrar JE, Triche T, Jr., et al. The molecular landscape
of pediatric acute myeloid leukemia reveals recurrent structural
alterations and age-specific mutational interactions. Nat Med
2018:24(1):103-112.
3. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic
abnormalities are predictive of induction success, cumulative incidence
of relapse, and overall survival in adult patients with de novo acute
myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).
Blood 2002:100(13):4325-4336.
4. Balgobind BV, Zwaan CM, Pieters R, et al. The heterogeneity of
pediatric MLL-rearranged acute myeloid leukemia. Leukemia
2011:25(8):1239-1248.
5. Song TY, Lee SH, Kim G, et al. Improvement of treatment outcome over
2 decades in children with acute myeloid leukemia. Blood Res
2018:53(1):25-34.
6. Shih LY, Liang DC, Fu JF, et al. Characterization of fusion partner
genes in 114 patients with de novo acute myeloid leukemia and MLL
rearrangement. Leukemia 2006:20(2):218-223.
7. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic
cytogenetics on outcome in AML: analysis of 1,612 patients entered into
the MRC AML 10 trial. The Medical Research Council Adult and Children’s
Leukaemia Working Parties. Blood 1998:92(7):2322-2333.
8. Raimondi SC, Chang MN, Ravindranath Y, et al. Chromosomal
abnormalities in 478 children with acute myeloid leukemia: clinical
characteristics and treatment outcome in a cooperative pediatric
oncology group study-POG 8821. Blood 1999:94(11):3707-3716.
9. Meyer C, Burmeister T, Groger D, et al. The MLL recombinome of acute
leukemias in 2017. Leukemia 2018:32(2):273-284.
10. Brooimans RA, van der Velden VHJ, Boeckx N, et al. Immunophenotypic
measurable residual disease (MRD) in acute myeloid leukemia: Is
multicentric MRD assessment feasible? Leuk Res 2019:76:39-47.
11. van der Velden VH, van der Sluijs-Geling A, Gibson BE, et al.
Clinical significance of flowcytometric minimal residual disease
detection in pediatric acute myeloid leukemia patients treated according
to the DCOG ANLL97/MRC AML12 protocol. Leukemia 2010:24(9):1599-1606.
12. Rubnitz JE, Inaba H, Dahl G, et al. Minimal residual
disease-directed therapy for childhood acute myeloid leukaemia: results
of the AML02 multicentre trial. Lancet Oncol 2010:11(6):543-552.
13. Konuma T, Mizuno S, Kondo T, et al. Allogeneic hematopoietic cell
transplantation in adult acute myeloid leukemia with 11q23 abnormality:
a retrospective study of the Adult Acute Myeloid Leukemia Working Group
of the Japan Society for Hematopoietic Cell Transplantation (JSHCT). Ann
Hematol 2018:97(11):2173-2183.
14. Armand P, Kim HT, Zhang MJ, et al. Classifying cytogenetics in
patients with acute myelogenous leukemia in complete remission
undergoing allogeneic transplantation: a Center for International Blood
and Marrow Transplant Research study. Biol Blood Marrow Transplant
2012:18(2):280-288.
15. Creutzig U, van den Heuvel-Eibrink MM, Gibson B, et al. Diagnosis
and management of acute myeloid leukemia in children and adolescents:
recommendations from an international expert panel. Blood
2012:120(16):3187-3205.
16. Kaspers GJ. Pediatric acute myeloid leukemia. Expert Rev Anticancer
Ther 2012:12(3):405-413.
17. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the
World Health Organization (WHO) classification of myeloid neoplasms and
acute leukemia: rationale and important changes. Blood
2009:114(5):937-951.
18. Smith ML, Hills RK, Grimwade D. Independent prognostic variables in
acute myeloid leukaemia. Blood Rev 2011:25(1):39-51.
19. von Neuhoff C, Reinhardt D, Sander A, et al. Prognostic impact of
specific chromosomal aberrations in a large group of pediatric patients
with acute myeloid leukemia treated uniformly according to trial AML-BFM
98. J Clin Oncol 2010:28(16):2682-2689.
20. Ravindranath Y, Chang M, Steuber CP, et al. Pediatric Oncology Group
(POG) studies of acute myeloid leukemia (AML): a review of four
consecutive childhood AML trials conducted between 1981 and 2000.
Leukemia 2005:19(12):2101-2116.
21. Niewerth D, Creutzig U, Bierings MB, et al. A review on allogeneic
stem cell transplantation for newly diagnosed pediatric acute myeloid
leukemia. Blood 2010:116(13):2205-2214.
22. Zwaan CM, Kolb EA, Reinhardt D, et al. Collaborative Efforts Driving
Progress in Pediatric Acute Myeloid Leukemia. J Clin Oncol
2015:33(27):2949-2962.